Paul Tonko: “I have an amendment at the desk. The Acting CHAIR. The Clerk will designate the amendment. The text of the amendment is…”

“I have an amendment at the desk. The Acting CHAIR. The Clerk will designate the amendment. The text of the amendment is as follows: Add at the end of title VIII the following (and conform the table of contents accordingly): SEC. 812. ADDITION OF NEW MEASURES BASED ON ACCESS TO BIOSIMILAR BIOLOGICAL PRODUCTS TO THE 5-STAR RATING SYSTEM UNDER MEDICARE ADVANTAGE. (a) In General.--Section 1853(o)(4) of the Social Security Act (42 U.S.C. 1395w-23(o)(4)) is amended by adding at the end the following new subparagraph: ``(E) Addition of new measures based on access to biosimilar biological products.-- ``(i) In general.--For 2021 and subsequent years, the Secretary shall add a new set of measures to the 5-star rating system based on access to biosimilar biological products covered under part B and, in the case of MA-PD plans, such products that are covered part D drugs. Such measures shall assess the impact a plan's benefit structure may have on enrollees' utilization of or ability to access biosimilar biological products, including in comparison to the reference biological product, and shall include measures, as applicable, with respect to the following: ``(I) Coverage.--Assessing whether a biosimilar biological product is on the plan formulary in lieu of or in addition to the reference biological product. ``(II) Preferencing.--Assessing tier placement or cost- sharing for a biosimilar biological product relative to the reference biological product.…”